Anzeige
Mehr »
Mittwoch, 03.09.2025 - Börsentäglich über 12.000 News
Geheime Uran-Aktie: Ist das der historische "New Deal"-Moment für amerikanischen Uransektor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7LZ | ISIN: KYG1933S1012 | Ticker-Symbol: N/A
NASDAQ
02.09.25 | 22:00
2,300 US-Dollar
0,00 % 0,000
1-Jahres-Chart
CASI PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CASI PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur CASI PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors121- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations- Operating...
► Artikel lesen
FrCASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results2.573SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies...
► Artikel lesen
DoCASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025164SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with...
► Artikel lesen
CASI PHARMACEUTICALS Aktie jetzt für 0€ handeln
27.08.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer2
04.08.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer1
04.08.CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection326CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopePhase 1 study in adults with active and chronic active renal allograft AMR planned to initiateAMR is...
► Artikel lesen
21.07.CASI Pharmaceuticals announces CEO appointment12
21.07.CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program1.164-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record...
► Artikel lesen
19.05.CASI Pharmaceuticals Provides Business and Clinical Update1.055BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
16.05.CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results394BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
14.05.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer1
12.05.CASI Pharmaceuticals to divest Chinese assets in $20 million deal2
12.05.CASI Pharmaceuticals veräußert Eigenkapital in chinesischen Tochtergesellschaften3
12.05.CASI Pharmaceuticals divests equity in Chinese subsidiaries6
12.05.CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China293BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
07.05.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer4
07.05.CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement726BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...
► Artikel lesen
09.04.CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer5
03.04.CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company379BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...
► Artikel lesen
31.03.CASI Pharmaceuticals, Inc. - 20-F, Annual and transition report of foreign private issuers3
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1